Achieving the Selectivity Required for the Elusive Trifecta of Safety, Efficacy, & Convenience in IBD Drug Development

Time: 11:00 am
day: Conference Day Two


  • Driving high selectivity of integrin-targeted medicines with Morphic’s MInT Platform
  • Leveraging understanding of integrin structure and function to develop novel molecules designed to achieve the potency, high selectivity, and pharmaceutical properties required for oral administration
  • Employing innovative end points to accelerate decision making for POC studies in IBD